New oral diabetes drug shows promise in early safety trial

NCT ID NCT05086445

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called LY3502970 in Japanese adults with type 2 diabetes. The main goal is to check for side effects and see how the body processes the drug. Participants take either the drug or a placebo and are monitored over up to 24 weeks with blood tests and clinic visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental oral drug called LY3502970
What this could lead to
If successful, this could lead to a new oral medication option for managing blood sugar in people with type 2 diabetes.
What could go wrong
This is an early phase 1 trial focused on safety, so it is too soon to know if the drug works well. Side effects are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Research Hospital Tokyo

    Shinjuku-ku, Tokyo, 162-0053, Japan

  • Medical Corporation Heishinkai OPHAC Hospital

    Osaka, Osaka, 532-0003, Japan

  • Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic

    Toshima City, Tokyo, 171-0014, Japan

  • P-One Clinic

    Hachiōji, Tokyo, 192-0071, Japan

  • Yokohama Minoru Clinic

    Yokohama, 232-0064, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.